Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), uti
CPT4 code
Name of the Procedure:
Mass Spectrometric Analysis of Galectin-3-Binding Protein and Scavenger Receptor Cysteine-Rich Type 1 Protein M130 in Oncology (Lung), with Clinical Risk Factor Assessment
Summary
This procedure involves using advanced mass spectrometry to analyze specific proteins in lung tissue related to cancer. It integrates the analysis of five clinical risk factors: age, smoking status, nodule diameter, nodule-spiculation status, and nodule location, to aid in the diagnosis and treatment planning of lung cancer.
Purpose
This procedure addresses the detection and assessment of lung cancer. The main goals are to accurately diagnose lung cancer, evaluate its progression, and tailor treatment plans based on a detailed molecular and clinical profile.
Indications
- Presence of lung nodules detected on imaging.
- Suspicion of lung cancer based on symptoms such as persistent cough, unexplained weight loss, or breathing difficulties.
- High-risk individuals (e.g., heavy smokers or older adults).
Preparation
- Patients may need to fast for a few hours before the procedure.
- Pre-procedure imaging tests such as CT scans or MRIs may be required.
- Adjustments to medications might be necessary, depending on patient health status and clinician recommendations.
Procedure Description
- The procedure begins with a biopsy to obtain lung tissue samples.
- The tissue samples are processed and prepared for mass spectrometric analysis.
- Using mass spectrometry, the levels of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130 are quantified.
- These protein levels are then analyzed in conjunction with clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status, and nodule location).
- A comprehensive report is prepared to assist clinicians in diagnosing and planning treatment.
Tools and Equipment:
- Biopsy needles or surgical instruments for tissue collection.
- Mass spectrometer and associated lab equipment.
Anesthesia: Local anesthesia for biopsy or general anesthesia if a surgical approach is needed.
Duration
The biopsy procedure typically takes about 30 minutes to 1 hour. The analysis and report preparation may take several days.
Setting
Conducted initially in a hospital for the biopsy. The tissue analysis occurs in a specialized laboratory.
Personnel
- Pulmonologist or thoracic surgeon performs the biopsy.
- Laboratory technicians and pathologists conduct the mass spectrometric analysis.
- Oncologists and radiologists interpret the results.
Risks and Complications
- Biopsy-related risks: bleeding, infection, or pneumothorax.
- Rare complications may include damage to lung tissue.
Benefits
- Provides a precise molecular and clinical profile of lung nodules.
- Aids in early and accurate diagnosis of lung cancer.
Helps tailor personalized treatment plans for better outcomes.
Recovery
- Post-biopsy care may include monitoring for any immediate complications, such as bleeding or infection.
- Patients are typically advised to rest for the remainder of the day.
- Follow-up appointments may be necessary to discuss results and plan further treatment.
Alternatives
- Traditional imaging techniques (CT, MRI) without mass spectrometric analysis.
- Surgical biopsy with histopathological examination.
- These alternatives may be less precise in providing molecular details but can still aid in diagnosis.
Patient Experience
- The biopsy may cause temporary discomfort or pain.
- Anesthesia helps minimize pain during tissue collection.
- Post-procedure, patients might experience mild soreness or bruising at the biopsy site.
- Results from mass spectrometric analysis can provide valuable insights, reducing overall anxiety by guiding appropriate treatment planning.